Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab

Abstract

Abbreviations & Acronyms AMACR = a-methylacyl CoA racemase ANN = artificial neural networks BSI = bone scan index CT = computed tomography FDG-PET = fluorodeoxyglucose-positron emission tomography HLA = human leukocyte antigen HS(n) = Hot spot number IMDC = International Metastatic RCC Database Consortium IO = immune-oncology MTSCC = mucinous tubular and spindle cell carcinoma RCC = renal cell carcinoma TKIs = tyrosine kinase inhibitors WHO = World Health Organization

Mucinous Tubular and Spindle Cell Renal Cell Carcinoma (MTSC-RCC) with an Unusual Presentation in a Child

“…The MTSC-RCC is a rare variant of renal cell carcinoma. This entity has been recently identified as a separate variant of RCC and had been classified in the 2004 World Health its rarity, there are few reports of response to Sunitinib, Gemitcitabine, or immunotherapy (ipilimumab and nivolumab) in a case of metastatic MTSC-RCC (10)(11)(12). In our case, the intraoperative findings precluded a safe surgical excision, and hence we had to resort to alternate strategies.…”

High-Grade Renal Mucinous Tubular and Spindle Cell Carcinoma

“…Larkin et al [15] presented a case of metastatic MTSCC that responded to sunitinib (tyrosine kinase inhibitor). In addition, Fuchizawa et al [16] presented a case of metastatic MTSCC that achieved lasting complete remission of bone metastases after cytoreductive nephrectomy followed by the combination of immune-oncology (IO) drugs nivolumab and ipilimumab. They also reported that immunohistochemical analyses of the tumor-infiltrating immune cells predicted the efficacy of immune checkpoint inhibitors for nonclear RCCs including MTSCC [16].…”

“…In addition, Fuchizawa et al [16] presented a case of metastatic MTSCC that achieved lasting complete remission of bone metastases after cytoreductive nephrectomy followed by the combination of immune-oncology (IO) drugs nivolumab and ipilimumab. They also reported that immunohistochemical analyses of the tumor-infiltrating immune cells predicted the efficacy of immune checkpoint inhibitors for nonclear RCCs including MTSCC [16]. We will consider the IO combination or IO-tyrosine kinase inhibitor combination according to the International Metastatic RCC Database Consortium (IMDC) risk classification if recurrence is observed.…”

Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report

“…Only one case report regarding the combination of nivolumab plus ipilimumab for metastatic MTSCC after cytoreductive nephrectomy has been reported, showing some efficacy (9). To our knowledge, however, this is the first reported case of cytoreductive nephrectomy after combination of nivolumab plus ipilimumab for MTSCC of the kidney with bone metastases.…”

“…and monotherapy of immune checkpoint inhibitors reported in only a few case reports (3)(4)(5)(6)(7)(8). Only one case report regarding the combination of nivolumab plus ipilimumab for metastatic MTSCC after cytoreductive nephrectomy has recently been reported, showing some efficacy (9).…”